{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: India Drug Manufacturers - General news", "home_page_url": "https://sharemaestro.com/newsreel/in/healthcare/drug-manufacturers-general/", "feed_url": "https://sharemaestro.com/newsreel/in/healthcare/drug-manufacturers-general/feed.json", "description": "Latest Drug Manufacturers - General company headlines from India, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:0dd11d1ca2c6ca1fb1ad59f4430706c6828548d069499c031fd0c15382fb78d5", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Kopran Consolidated June 2026 Net Sales at Rs 153.99 crore, up 11.91% Y-o-Y", "content_text": "Kopran Consolidated June 2026 Net Sales at Rs 153.99 crore, up 11.91% Y-o-Y", "date_published": "2026-08-14T06:30:38+00:00", "authors": [{"name": "Moneycontrol.com"}], "tags": ["Market update", "KOPRAN"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KOPRAN", "name": "Kopran Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e1ff2616-e10d-4db1-92e2-1bf40cba2ecc/"}]}}, {"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:d8bd6c59b945f6f64e0515995737be27fbc3ac410c39e28153e248143da19559", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQcTJrNDlvU1FzWFVoSi1ueGhZWnhfeElhSkxlOWdYQ040V2tkaWtqclBDLTh5NU5NbVNFN24xRGtYUE9XT3lMc2VPeG41amFNRUJoRVN5cFFQVTByZWU3bDZHN0FDWmd4YnhfOTBndzQ3OFNlcnRNR1BjZjE4TVRFVWhvajNETUstejhpUA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQcTJrNDlvU1FzWFVoSi1ueGhZWnhfeElhSkxlOWdYQ040V2tkaWtqclBDLTh5NU5NbVNFN24xRGtYUE9XT3lMc2VPeG41amFNRUJoRVN5cFFQVTByZWU3bDZHN0FDWmd4YnhfOTBndzQ3OFNlcnRNR1BjZjE4TVRFVWhvajNETUstejhpUA?oc=5", "title": "TTK Healthcare Yearly results, Financial Summary", "content_text": "TTK Healthcare Yearly results, Financial Summary", "date_published": "2026-08-13T22:32:51+00:00", "authors": [{"name": "The Economic Times"}], "tags": ["Earnings", "TTKHLTCARE"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TTKHLTCARE", "name": "TTK Healthcare Limited", "sentiment_url": "https://sharemaestro.com/sentiment/d8a601d8-7d12-4eff-b6fe-918c2eed36b0/"}]}}, {"id": "source:33e32a55454fb0399fcd532ed23175ffd075d37280d0c841a24aff8a18065e15", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "title": "How Pfizer\u2019s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story", "content_text": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50\u2013US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer's autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology and dermatology pipeline. We'll now explore how Pfizer's higher 2026 revenue guidance, backed by non-COV", "date_published": "2026-08-13T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:713515b88b04620bc0ce1e81f52c874b1f69127f1e2f900bbf6fe7452cecab5f", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOGswNFZ0by11d3RqVnBHYS04TTRHSG5xR0JTNTlUQTd1VkItQkpLZXdCSjRMZXBuQkQ1TnYyWEUxTzFfejVKM0ctQVZoZlBNRkIxNjRuWWhFQzl4eU4zUm83RXNfSkloUDFCanFCbGhYaGZUYVlWTVVkRU5UaFJOTl8xYzhoZHh0NjNCZW44QlFxQVBxMk5ZdnloWm40ckotOVhMaVItWmxyMlEwNmRVRTlSWTNyaDF0UDZVNXlMSm9GaFdXOGNBSDYxXzNjTDhWZmJSN0FfenJJVFR4OG83eUNpZ0xyRmc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOGswNFZ0by11d3RqVnBHYS04TTRHSG5xR0JTNTlUQTd1VkItQkpLZXdCSjRMZXBuQkQ1TnYyWEUxTzFfejVKM0ctQVZoZlBNRkIxNjRuWWhFQzl4eU4zUm83RXNfSkloUDFCanFCbGhYaGZUYVlWTVVkRU5UaFJOTl8xYzhoZHh0NjNCZW44QlFxQVBxMk5ZdnloWm40ckotOVhMaVItWmxyMlEwNmRVRTlSWTNyaDF0UDZVNXlMSm9GaFdXOGNBSDYxXzNjTDhWZmJSN0FfenJJVFR4OG83eUNpZ0xyRmc?oc=5", "title": "Earnings call transcript: Marksans Pharma posts strong Q1 2026 profit, misses revenue view", "content_text": "Earnings call transcript: Marksans Pharma posts strong Q1 2026 profit, misses revenue view", "date_published": "2026-08-13T12:12:00+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:ca7bd9b0749ebb6a787227418d9a91b874566d623be8c3cd9e785328575d4a6f", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "title": "5 Insightful Analyst Questions From Pfizer\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to \"continued strategic progress\" and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands ", "date_published": "2026-08-13T02:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:557d79d63f2a548ef881cad1f22b9766c488b110ba208f8722c0464e98c1e4e4", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNemQ4Vmw5MXRpTFV4YjlrS2tmQWQzcWJTSno4VE5sOHBBX0NfZWEtelphTEJoWU1OZ0JhVWF6aDBaZWFrNHJVMUs4eGZTUWRybW5jUGpVRDZXa3R5SGdkLUFkbUpSTEExcVZJTDA0WXNxS01QcEZ0Q1lYa2NUOHd4OGJUSlJjNnE3SHZTbDZEZmZ5WEhSOFlvVnVjWXdCeVRRSGFYY2NiZzJyWVRvZnFsZ0l5aDctU0lfUDY4Y0Rob1M?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNemQ4Vmw5MXRpTFV4YjlrS2tmQWQzcWJTSno4VE5sOHBBX0NfZWEtelphTEJoWU1OZ0JhVWF6aDBaZWFrNHJVMUs4eGZTUWRybW5jUGpVRDZXa3R5SGdkLUFkbUpSTEExcVZJTDA0WXNxS01QcEZ0Q1lYa2NUOHd4OGJUSlJjNnE3SHZTbDZEZmZ5WEhSOFlvVnVjWXdCeVRRSGFYY2NiZzJyWVRvZnFsZ0l5aDctU0lfUDY4Y0Rob1M?oc=5", "title": "Marksans Pharma Q1 Results: Net profit rises 174% YoY to \u20b91,594 crore", "content_text": "Marksans Pharma Q1 Results: Net profit rises 174% YoY to \u20b91,594 crore", "date_published": "2026-08-12T12:44:05+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:3af3d30d86f1ab2ed306d7390b6de592b1f944fc1a78ebf3cdb402ca06fa1b12", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Marksans Pharma shares rally over 9% after Q1 profit spikes 174% YoY to Rs 159 crore", "content_text": "Marksans Pharma shares rally over 9% after Q1 profit spikes 174% YoY to Rs 159 crore", "date_published": "2026-08-12T09:52:23+00:00", "authors": [{"name": "The Economic Times"}], "tags": ["Earnings", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:4b7ce4dc2cfe98e087d817dbcf1f54e50fab99755dd09fb5dddcaa23a41457b8", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOSkE4emVVemFYVjFKWE5EUGt5RFNNYTIxcURvV3BtcnRnU0MxQUthVTllLXUwSXpsRmh6RnBiV3ViMHN2MEFUdG10OFNuN2tXTG1DYzF4SExETkxFdmtHbE1GTEpuZEZMaUVLbE5BUmNRSDZxMjI4cV9MZWJqWG9RalZTelc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOSkE4emVVemFYVjFKWE5EUGt5RFNNYTIxcURvV3BtcnRnU0MxQUthVTllLXUwSXpsRmh6RnBiV3ViMHN2MEFUdG10OFNuN2tXTG1DYzF4SExETkxFdmtHbE1GTEpuZEZMaUVLbE5BUmNRSDZxMjI4cV9MZWJqWG9RalZTelc?oc=5", "title": "Marksans Pharma Hits 52-Week High, Shares Jump 14%", "content_text": "Marksans Pharma Hits 52-Week High, Shares Jump 14%", "date_published": "2026-08-12T09:14:24+00:00", "authors": [{"name": "Equitypandit"}], "tags": ["Market update", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:31912b968010dc25d8698969b6b33f7e90ee1079fc70085323ff86162825ba77", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Marksans Pharma Q1 Results: Shares jump 11% after profit nearly triples, margin expands", "content_text": "Marksans Pharma Q1 Results: Shares jump 11% after profit nearly triples, margin expands", "date_published": "2026-08-12T07:30:57+00:00", "authors": [{"name": "CNBC TV18"}], "tags": ["Earnings", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:17d9fe45e9cb33e1cc2f028231a03bc8488e692a8a27344762fedd60cd8edb90", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNb3VHWTlPSVhINHB3VXc0djVZeERBUU5xVGNOV0VVeG1KZU85aU5YTmZpRDM2dV9oMl9UOVRzY1hjUXVLYldlWGpxV0x3bVpBZVdXR0NLWWZZaDNwbWVXTFI5NG5rWHdyRVNkVnFNS1pnWUZxVGRWT1ZZcWFsSktCYVhLMjBPM0picWhVMUdfSnlHWTNXa3Zyd2pSb183ckpKTFdjclZ4NE12SmV1ejlVZU54dGZ3aEMzcGRUcFBzY0h3ZGpoc041bGZjNXliUWMtX2w4YUVPeWpQd9IB2gFBVV95cUxNb3VHWTlPSVhINHB3VXc0djVZeERBUU5xVGNOV0VVeG1KZU85aU5YTmZpRDM2dV9oMl9UOVRzY1hjUXVLYldlWGpxV0x3bVpBZVdXR0NLWWZZaDNwbWVXTFI5NG5rWHdyRVNkVnFNS1pnWUZxVGRWT1ZZcWFsSktCYVhLMjBPM0picWhVMUdfSnlHWTNXa3Zyd2pSb183ckpKTFdjclZ4NE12SmV1ejlVZU54dGZ3aEMzcGRUcFBzY0h3ZGpoc041bGZjNXliUWMtX2w4YUVPeWpQdw?oc=5", "title": "Marksans Pharma Stock Jumps 11% After Net Profit Jumps 2.5x, Revenue Surges 36%", "content_text": "Marksans Pharma Stock Jumps 11% After Net Profit Jumps 2.5x, Revenue Surges 36%", "date_published": "2026-08-12T07:29:55+00:00", "authors": [{"name": "NDTV Profit"}], "tags": ["Earnings", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:5b2a3e0474743f071cb79aaa3ce5771077914c8d06de8777a1dd97ed0207f760", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNNjhyYnZNQ0NNUlVEUXBjVzBOZDlqWjM0dXlhdGp2R1JObDR2TVlfNW1xdVFNeXpWd0RBcGtQcnpBQThHWTlhN3AyTzFaOGZ0eTgyMzNUTmliV1gzd2MxR1psdktyeTlMY3l1a01rWVJNNk5yUHF0ZXVTZHFXT1Q3RmlMMjVLcFpQTGFjQnI4V0I5TkplUVZGdFlSUXlYdDM5a1E3Q0ZZWHBkY2I4WFE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNNjhyYnZNQ0NNUlVEUXBjVzBOZDlqWjM0dXlhdGp2R1JObDR2TVlfNW1xdVFNeXpWd0RBcGtQcnpBQThHWTlhN3AyTzFaOGZ0eTgyMzNUTmliV1gzd2MxR1psdktyeTlMY3l1a01rWVJNNk5yUHF0ZXVTZHFXT1Q3RmlMMjVLcFpQTGFjQnI4V0I5TkplUVZGdFlSUXlYdDM5a1E3Q0ZZWHBkY2I4WFE?oc=5", "title": "MARKSANS PHARMA. Share Price Today Up 10%", "content_text": "MARKSANS PHARMA. Share Price Today Up 10%", "date_published": "2026-08-12T07:09:00+00:00", "authors": [{"name": "Equitymaster"}], "tags": ["Market update", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:b32e8941adc1f7e3a510ca5d37a824784d23ee6ca99d77bc545c7074dde26359", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPa0ZraTYyTjJUckszbmF3OG5RWlp4dmJEMkZqWloxa2l3MzBRVVIxcTJuaG1yUkN5S1RnVWhydzFoTG1KbGhyeUUyZmVXYjQwRk9xVENod21YSmdrR1h2V1ctRXZmOFpPa29hazhnZVZ1U2dyWllsdnYzZ2dpeU5kNDBLWWpUWGxyblZ0eTNXcERsazdKcmxENXBteEVENHlWQVBZVF9PY3Q4VWlLVFVoY1BPS211SmlwczNITTZiZ3g?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPa0ZraTYyTjJUckszbmF3OG5RWlp4dmJEMkZqWloxa2l3MzBRVVIxcTJuaG1yUkN5S1RnVWhydzFoTG1KbGhyeUUyZmVXYjQwRk9xVENod21YSmdrR1h2V1ctRXZmOFpPa29hazhnZVZ1U2dyWllsdnYzZ2dpeU5kNDBLWWpUWGxyblZ0eTNXcERsazdKcmxENXBteEVENHlWQVBZVF9PY3Q4VWlLVFVoY1BPS211SmlwczNITTZiZ3g?oc=5", "title": "Marksans Pharma posts record EBITDA of \u20b9213 cr in Q1FY27", "content_text": "Marksans Pharma posts record EBITDA of \u20b9213 cr in Q1FY27", "date_published": "2026-08-12T07:08:27+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Market update", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:d936ea597992f68883228c46de03f25cf4cbf918eeb62deae0bbb32d6f964680", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-agreed-44-million-053939481.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-agreed-44-million-053939481.html", "title": "Pfizer (PFE) Agreed To A $44 Million Chantix Settlement", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. Both developments arrive as investors track Pfizer's legal exposures alongside late stage trial data that could inform future portfolio and r", "date_published": "2026-08-12T05:39:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:b162a3ee95312dfce7ca83346d22de9e2a7795c2001d34406bc76251206153e4", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-q2-2026-earnings-160001515.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-q2-2026-earnings-160001515.html", "title": "Pfizer (PFE) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific Officer - Chris Boshoff Chief Investor Relations Officer and Senior Vice President - Francesca DeMartino Full Conference Call Transcript Operator: Good day, everyone, and welcome to Pfizer's Second Quarter 2026 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call", "date_published": "2026-08-11T16:00:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:85f600c286003b2872baa3897747d4fe35e679a79e531155df99048f818c2ef6", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-inc-pfe-vs-biontech-123110407.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-inc-pfe-vs-biontech-123110407.html", "title": "Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?", "content_text": "Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down very different paths. One is leveraging massive scale and aggressive cost-cutting to protect profits, while the other is absorbing heavy losses to fund a corporate transition into oncology under new leadership.Pfizer vs. BioNTech: Which Pharma Giant Is Better Positioned", "date_published": "2026-08-11T12:31:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:27dfc067c78ba230450d50840262562ac47a24550b7cd3cd9f90c9ceb485a203", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRlFPVGNIV3czWDRRdHc5UzVFODMwcDZtUmU1QXotUW52OEhDa1ZnTHo1ODVUTGN2VjdRTVFIYmc2RGd0dzI3WEJkdXktSE1aanBMeUZjbDBJRkF3bF9tM0lNV2ZJakEyOUJpWURGNjhDVFl4aW9KTGhmU3QxaDR4ZVFxc3Q5b21yMGE4Tmk1VnFMNk1YdlBkQzZtSUtLb0cwTDVUVnp3UlJEQU1hQUNWd2tLbXlxbUk0WndiSUFPNjVzM00?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRlFPVGNIV3czWDRRdHc5UzVFODMwcDZtUmU1QXotUW52OEhDa1ZnTHo1ODVUTGN2VjdRTVFIYmc2RGd0dzI3WEJkdXktSE1aanBMeUZjbDBJRkF3bF9tM0lNV2ZJakEyOUJpWURGNjhDVFl4aW9KTGhmU3QxaDR4ZVFxc3Q5b21yMGE4Tmk1VnFMNk1YdlBkQzZtSUtLb0cwTDVUVnp3UlJEQU1hQUNWd2tLbXlxbUk0WndiSUFPNjVzM00?oc=5", "title": "Kopran net profit falls 10% to \u20b9670.09 lakh in Q1FY26 as margins compress", "content_text": "Kopran net profit falls 10% to \u20b9670.09 lakh in Q1FY26 as margins compress", "date_published": "2026-08-10T07:00:00+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "KOPRAN"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KOPRAN", "name": "Kopran Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e1ff2616-e10d-4db1-92e2-1bf40cba2ecc/"}]}}, {"id": "source:754eb55fa616be18d7d9d6f68db0e6d4317e485ba2fd308186555c4b0d96516a", "url": "https://seekingalpha.com/news/4629566-insider-trades-microsoft-meta-pfizer-among-notable-names?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629566-insider-trades-microsoft-meta-pfizer-among-notable-names?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Insider trades: Microsoft, Meta, Pfizer among notable names", "content_text": "[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small part of their positions in the company this week. EVP and Chief Marketing Officer Takeshi Numoto sold 4,810 shares at $496.48 each for ~$2.39M. The transaction represented about 10.13% of his direct holdings, leaving him", "date_published": "2026-08-08T15:03:14+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:1f6f15a2f6ded651c5478f7cbc6bbd42ad9f139a81835e6ac21e44eafc9f8a1e", "url": "https://www.nasdaq.com/articles/pfizers-next-weight-loss-weapon-how-berobenatide-stacks-against-novo-nordisks-wegovy-and", "external_url": "https://www.nasdaq.com/articles/pfizers-next-weight-loss-weapon-how-berobenatide-stacks-against-novo-nordisks-wegovy-and", "title": "Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound", "content_text": "Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer \u203a The past few years have been rough on Pfizer(NYSE: PFE). The company has generally posted subpar financial results due to weakness within its coronavirus franchise, which once helped it become the first biopharmaceutical company to achieve $100 billion in annual sales. The drugmaker is looking to turn things around by developing potential blockbuster pro", "date_published": "2026-08-07T22:55:29.259455+00:00", "authors": [{"name": "The Motley Fool"}], "tags": ["Earnings", "PFIZER"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFIZER", "name": "Pfizer Limited", "sentiment_url": "https://sharemaestro.com/sentiment/5a7a871a-3ec8-4ed1-9897-e06cf55d4e0c/"}]}}, {"id": "source:f5367781eb251416cfd1ac091dedcf10a4802eeae2bdbc980e5901d6a930c70c", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPOWliVW5rY200cHkzb2dzQndMeV9UX2JibVA3YkdqcFI0RjNrcFRlWGQxUnozZEpsTlM3bi0wMWJHdjF5eW9SdE53V0s0UEJValVEbWROTzV3ejBvOUh2b0lVZmFSQUhLLVIwWTQ4dGNOSWd1V0NOaGd0aEZsMzFqNzJFVG1fWUFvS013ZGxnMnJGamxwcm9qcmdjWGdzSXViS0o3RHQ3ckYyeTk2VEc0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPOWliVW5rY200cHkzb2dzQndMeV9UX2JibVA3YkdqcFI0RjNrcFRlWGQxUnozZEpsTlM3bi0wMWJHdjF5eW9SdE53V0s0UEJValVEbWROTzV3ejBvOUh2b0lVZmFSQUhLLVIwWTQ4dGNOSWd1V0NOaGd0aEZsMzFqNzJFVG1fWUFvS013ZGxnMnJGamxwcm9qcmdjWGdzSXViS0o3RHQ3ckYyeTk2VEc0?oc=5", "title": "Kopran Q1 Results: Net profit drops 10% YoY to \u20b9670 lakh", "content_text": "Kopran Q1 Results: Net profit drops 10% YoY to \u20b9670 lakh", "date_published": "2026-08-07T12:25:31+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "KOPRAN"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KOPRAN", "name": "Kopran Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e1ff2616-e10d-4db1-92e2-1bf40cba2ecc/"}]}}, {"id": "source:8c5a365d85cd301ada6726346165b7428b339e19863b759034e6e695f58ac037", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQOXl5N19FenNJY3BWT09HTC1BOU5QNzlPRHI5WTVYRUhVNjh3Mmp1OGxjQ1pUOFRET05adl9aX0V0RFk5VkRnaUtzc2dqR2VRQUdWZXlUV3hsVGV3S2JTd1ZCcnU1Uzh1VUZjdG1LTndhc3pBUGk5eHc4MVpPdXp0c0NHMExVX3d6bVFnR2FaRndoR2FIdlRIeTBBdzdxbzdudUo4NkRmbWNiMEkzd0JENVI3VkdnMDUtSHdIRUM2T3I5d1NBTVM4OGNaSkFkdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQOXl5N19FenNJY3BWT09HTC1BOU5QNzlPRHI5WTVYRUhVNjh3Mmp1OGxjQ1pUOFRET05adl9aX0V0RFk5VkRnaUtzc2dqR2VRQUdWZXlUV3hsVGV3S2JTd1ZCcnU1Uzh1VUZjdG1LTndhc3pBUGk5eHc4MVpPdXp0c0NHMExVX3d6bVFnR2FaRndoR2FIdlRIeTBBdzdxbzdudUo4NkRmbWNiMEkzd0JENVI3VkdnMDUtSHdIRUM2T3I5d1NBTVM4OGNaSkFkdw?oc=5", "title": "Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2026", "content_text": "Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2026", "date_published": "2026-08-07T09:35:47+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Earnings", "KOPRAN"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KOPRAN", "name": "Kopran Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e1ff2616-e10d-4db1-92e2-1bf40cba2ecc/"}]}}, {"id": "source:30830bc6a26c3b8105241f29476167bf09982540cd40a0e23b110e78f2e6d410", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNN0RRbFhobWMzT3QyWk9hTE9ObVFELWVJQWFOLXdDNWtDQlY2dlhXRGJXMThmZnVfZUloLWdzSnNjRUZXTVFuSm1kbmNBSmVhQkZJcXkwX01idEdfQVBEdGlTX25JQk10RDZrYWwxYkoxeHRFT2NINmdkV1ZhMU4ydU9idHFZd1p6aUt3MWZIWXBRckJSdVlMaFVYR3hSZTA3S2tiRg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNN0RRbFhobWMzT3QyWk9hTE9ObVFELWVJQWFOLXdDNWtDQlY2dlhXRGJXMThmZnVfZUloLWdzSnNjRUZXTVFuSm1kbmNBSmVhQkZJcXkwX01idEdfQVBEdGlTX25JQk10RDZrYWwxYkoxeHRFT2NINmdkV1ZhMU4ydU9idHFZd1p6aUt3MWZIWXBRckJSdVlMaFVYR3hSZTA3S2tiRg?oc=5", "title": "Kopran Q1 Consolidated Net Profit At \u20b96.7 Crore Vs \u20b97.5 Crore YoY", "content_text": "Kopran Q1 Consolidated Net Profit At \u20b96.7 Crore Vs \u20b97.5 Crore YoY", "date_published": "2026-08-07T09:16:02+00:00", "authors": [{"name": "Sahi"}], "tags": ["Earnings", "KOPRAN"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KOPRAN", "name": "Kopran Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e1ff2616-e10d-4db1-92e2-1bf40cba2ecc/"}]}}, {"id": "source:c1650e07c5b94cfeab7a85cbadf4941cc308d2c97f2ee21aad75bf98134ac809", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNaVh0VE91ZXhNMUpKUWNVZDFRY0ktRGstRDI3TWdFbzkxblRNdU1DSi1fV3hfMWgzM0RLalFROW9KaUlOSzIyaE5ZNkR3cTNvb2xHb041RFQ0ODRMWE5WVmx1M3pVUlJIal84bEM3U2tFLVpvR1JYaVhwR0R1aEJPcUoyNUFMYlJ1ck1PaXoxYW4wMUtxMmFybEttRmlFWnlyRGJMaXVwX3RDbWVDaXVQQ1FsdzFZM2hIcjhOc1BvS09TTlY5UTVJQjFoU3pvclNxVW9leTBrSFFIMzBFY1FBMEkxUHN0ZFnSAewBQVVfeXFMT0tPR2EyRzZoNE9kcTF4MVFObE1wLVN5bWJwX0E5ZG9hZUIyRGlfR0RFaFBnM1RyZlIzMkdDal9udExVMDJBS3JJQm1zWFl3Ri1iZU9LcjVQLThQVzVaQnF0UVBoR1dUSm1ZWHF6U2JzVk5ZeThWTEpnckt0MEc0UUt3TjFQZkRPaU1vQ1dOTV9RNW5JcTRMTzZsTEhJODRRZlVVRy0zVFlPTHI5a2hlbmFyNVR0UGhBNXlHWVpsVlhTck1QNlhQRy1BbWhuRjEyQ21DRDByWXlRSzRMT2h3cWRzQUF1VmN5YWxGcmQ?oc=5", "title": "Kopran consolidated net profit declines 10.07% in the June 2026 quarter", "content_text": "Kopran consolidated net profit declines 10.07% in the June 2026 quarter", "date_published": "2026-08-07T08:40:48+00:00", "authors": [{"name": "Business Standard"}], "tags": ["Earnings", "KOPRAN"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KOPRAN", "name": "Kopran Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e1ff2616-e10d-4db1-92e2-1bf40cba2ecc/"}]}}, {"id": "source:4a2d4f4f95b1be0bea237badb8617ed5c6bce0970ddc1dee82c5ea0b28d6f745", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "TTK Healthcare Standalone June 2026 Net Sales at Rs 257.56 crore, up 13.75% Y-o-Y", "content_text": "TTK Healthcare Standalone June 2026 Net Sales at Rs 257.56 crore, up 13.75% Y-o-Y", "date_published": "2026-08-07T07:14:25+00:00", "authors": [{"name": "Moneycontrol.com"}], "tags": ["Market update", "TTKHLTCARE"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TTKHLTCARE", "name": "TTK Healthcare Limited", "sentiment_url": "https://sharemaestro.com/sentiment/d8a601d8-7d12-4eff-b6fe-918c2eed36b0/"}]}}, {"id": "source:02ba2de6436ca7ae3ef05a096f15b76c215ffe99cc6b22068a3da4ec9046551a", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPWC02SGlaQ0JLeThCdl9CN0xDV1RGTm91bHZhTkc4WHg5TFh6ZDdteWswbmlDYVU5R0ZTUjQ2VE1kY2FSb1c2QjM0Yi1CR0I1SzIwR29hcmJfemVqQkpNLWFQT2FuRTZOajljMjdVaWJhLVhEa0pZdkR3cXlsdUJ1ZG5wXzlyVjdubDVHQTdrQjVaaFN4d3A5WmMyMzFUSUt6NV8wd3p6UEV2S1BPZ2hGTXBR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPWC02SGlaQ0JLeThCdl9CN0xDV1RGTm91bHZhTkc4WHg5TFh6ZDdteWswbmlDYVU5R0ZTUjQ2VE1kY2FSb1c2QjM0Yi1CR0I1SzIwR29hcmJfemVqQkpNLWFQT2FuRTZOajljMjdVaWJhLVhEa0pZdkR3cXlsdUJ1ZG5wXzlyVjdubDVHQTdrQjVaaFN4d3A5WmMyMzFUSUt6NV8wd3p6UEV2S1BPZ2hGTXBR?oc=5", "title": "Marksans Pharma schedules Q1FY27 earnings call for August 13", "content_text": "Marksans Pharma schedules Q1FY27 earnings call for August 13", "date_published": "2026-08-03T07:00:00+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:a5734465a6cb0057b8864a6f289ee2ad558ac8baab12fb1ff1479d0325ef934b", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQeGFxeHBIb3ZkTndvWDhiVDBhaUdFcGxHLWRneUZoTFFncUJ1a2NjUG5xYkhWbkhac0psUGNVanp2Q1B0NEl1dGt1WURQcGJ5YXpjaHJUUTMtakxFdWdvaWw1Y0RqVkUtNWdVWjcyX2FxMERTMmJBVTIzWjZ4NHg1S2ljdUo2a21hazA5Q0dVNzhISVJKWmxGUm1McGZIa2tfOFB0OXZjX09mNzdB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQeGFxeHBIb3ZkTndvWDhiVDBhaUdFcGxHLWRneUZoTFFncUJ1a2NjUG5xYkhWbkhac0psUGNVanp2Q1B0NEl1dGt1WURQcGJ5YXpjaHJUUTMtakxFdWdvaWw1Y0RqVkUtNWdVWjcyX2FxMERTMmJBVTIzWjZ4NHg1S2ljdUo2a21hazA5Q0dVNzhISVJKWmxGUm1McGZIa2tfOFB0OXZjX09mNzdB?oc=5", "title": "Marksans Pharma hits record \u20b93,033 crore revenue, declares \u20b90.90 dividend", "content_text": "Marksans Pharma hits record \u20b93,033 crore revenue, declares \u20b90.90 dividend", "date_published": "2026-08-03T07:00:00+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}, {"id": "source:71ad1ac8843f7210ba1df50ad7fb8be9a1c56ac08485c1e6944be6b953d7875d", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNNmRPY1otWlExU0lNUUc1MlhmY2kxQ1duVHVxUEtiTFJvMlVwN3RhMnhqbnZVOTRnc2RnYlVQR2VIMFlKMDF5ZU5ldWFpVFRmaE41RXlMMmJiYWQzZGM4UE1tSDZ3ejFkYm1UTjBtSUFkcGZSbl9VblFqMXJDejNiYkxhQ1dYMVphVWFGLTNYMjZXZkxhOXRWU2N2Ql90bE1OcGJYclRfeHQ5WURNeTQ1VXZCalZiZ3hYWVNWMWxzQ1VaQkY2anR2b2tSaVF0Q3JxOWZXbTJzWHhCdFZsSFgyakw5ai1PSEhJQlotSE9zYXJfMHMxMWp5clpiVkRFVG9Hcm1tejhKVQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNNmRPY1otWlExU0lNUUc1MlhmY2kxQ1duVHVxUEtiTFJvMlVwN3RhMnhqbnZVOTRnc2RnYlVQR2VIMFlKMDF5ZU5ldWFpVFRmaE41RXlMMmJiYWQzZGM4UE1tSDZ3ejFkYm1UTjBtSUFkcGZSbl9VblFqMXJDejNiYkxhQ1dYMVphVWFGLTNYMjZXZkxhOXRWU2N2Ql90bE1OcGJYclRfeHQ5WURNeTQ1VXZCalZiZ3hYWVNWMWxzQ1VaQkY2anR2b2tSaVF0Q3JxOWZXbTJzWHhCdFZsSFgyakw5ai1PSEhJQlotSE9zYXJfMHMxMWp5clpiVkRFVG9Hcm1tejhKVQ?oc=5", "title": "SANOFICONR: Q2 2026 revenue up 7% and net profit at \u20b9919 million, driven by domestic sales growth", "content_text": "SANOFICONR: Q2 2026 revenue up 7% and net profit at \u20b9919 million, driven by domestic sales growth", "date_published": "2026-07-28T07:00:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "SANOFICONR"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SANOFICONR", "name": "SANOFI CONS HEALTHC IND L", "sentiment_url": "https://sharemaestro.com/sentiment/4af1d383-3971-4d5f-acf2-06b699156975/"}]}}, {"id": "source:cacb9337b0a3c65d3584d2e4ddfa6d473d1a46cf315de0d54c1980e6e2f99982", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNRXFOYmpuOVRXSDVZLWIxMXVkOTlkemlQd1l2N09kZE5OR3R2YlI3eWJnQi02emI4cXJYS3hSVVRRZ3FSdklhbGhtc1ZlZTRQSTBwUlpwMkgtbGpuSEV2Smw2UW5fSUNTNkFIQjBzNndxd3VNTDF2dXFSVHB3MFI5U0hZaEZReDNvZTJsdTdPT08za0RkTTg3c0MwNnZnZ01SX19HdGFsQUdaSGg3UFA2TkdFZW5jSmZDckRkMjNVSlFRbmEtOVNGUUo5dGEzd1hvYTBqRTlKOEp4QnM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNRXFOYmpuOVRXSDVZLWIxMXVkOTlkemlQd1l2N09kZE5OR3R2YlI3eWJnQi02emI4cXJYS3hSVVRRZ3FSdklhbGhtc1ZlZTRQSTBwUlpwMkgtbGpuSEV2Smw2UW5fSUNTNkFIQjBzNndxd3VNTDF2dXFSVHB3MFI5U0hZaEZReDNvZTJsdTdPT08za0RkTTg3c0MwNnZnZ01SX19HdGFsQUdaSGg3UFA2TkdFZW5jSmZDckRkMjNVSlFRbmEtOVNGUUo5dGEzd1hvYTBqRTlKOEp4QnM?oc=5", "title": "Kopran Latest Results: Consolidated Revenue \u20b968,142 Lakhs, Net Profit \u20b92,573 Lakhs in FY26", "content_text": "Kopran Latest Results: Consolidated Revenue \u20b968,142 Lakhs, Net Profit \u20b92,573 Lakhs in FY26", "date_published": "2026-07-25T07:00:00+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "KOPRAN"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KOPRAN", "name": "Kopran Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e1ff2616-e10d-4db1-92e2-1bf40cba2ecc/"}]}}, {"id": "source:7a522d4282335f5def1fcd2e280a43810a83b92a47b1b1bc873ebf01cc22126d", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQbEhoMFdrWlM4dGZDdjhnbW1xSVRCOW9ZbGEtMGZIUXpUOThLZUJLVVQ4WENRYUFpczZLeVNvUHBGY3I4Y04yck9ZNy1JSGpSYzR3LUxXQ19XektBMmtzQVJmZTBZLXBvZzc3YUVFdXN5Q0doV05xbklBWktWbDQ2Sy1KSldwQjNtMVNjUkJ1OU0tVjFvQlE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQbEhoMFdrWlM4dGZDdjhnbW1xSVRCOW9ZbGEtMGZIUXpUOThLZUJLVVQ4WENRYUFpczZLeVNvUHBGY3I4Y04yck9ZNy1JSGpSYzR3LUxXQ19XektBMmtzQVJmZTBZLXBvZzc3YUVFdXN5Q0doV05xbklBWktWbDQ2Sy1KSldwQjNtMVNjUkJ1OU0tVjFvQlE?oc=5", "title": "MARKSANS PHARMA. Share Price Today Down 4%", "content_text": "MARKSANS PHARMA. Share Price Today Down 4%", "date_published": "2026-07-21T07:00:00+00:00", "authors": [{"name": "Equitymaster"}], "tags": ["Market update", "MARKSANS"], "_sharemaestro": {"country": "India", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MARKSANS", "name": "Marksans Pharma Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3245c275-868e-4a9d-bf63-ea5505585f81/"}]}}]}